The Next Generation of PRP
Injectable Platelet Rich Fibrin (i-PRF) is the next generation of PRP. i-PRF offers an innovative concept to overcome previous limitations within regenerative medicine. i-PRF offers excellent cell viability and bio compatibility with superior tissue regeneration. This advanced form of platelet rich plasma does not use anticoagulants or other chemical based additives, therefore offers a completely natural treatment to improve volume loss, photo damage, fine lines and wrinkles, scars, pigmentation, poor texture and hair loss.
The low speed centrifugation concept (LSCC) guarantees a higher concentration of platelets, growth factors and leukocytes which become trapped within the fibrin mesh resulting in a cell rich network. These essential cells are then released slowly to lead to a natural regeneration process.
Studies prove the i-PRF Smart Cell System offers a significantly higher concentration of platelets when compared to PRP following centrifugation, which highlights the superiority of Injectable Platelet Rich Fibrin and why this system is a true game changer.
7 Fundamental growth factors are released by platelets:
EGF, PDGF, VGF, IGF, KGF, TGF-B, FGF
Platelets only release growth factors once activated.
Anticoagulant inhibits the activation of platelets
Leukocytes have a strong influence on the release of growth factors
Leukocyte rich plasma releases larger amounts of molecules
Superior for wound healing – scars and skin needling
i-PRF Smart Cell system contains activated platelets, leukocytes (WBC) & mesenchymal stem cells
The i-PRF Smart Cell system uses biocompatible medical device (class IIb) tubes specifically designed for autologous therapy
Fibrinogen is the key. The fibrin mesh traps the platelets, growth factors and bioactive molecules
i-PRF Smart Cell system is 100% natural, completely free of chemicals, additives or clotting factors
i-PRF does not use anti-coagulant. Anticoagulants inhibit tissue regeneration and platelet activation. Anticoagulant also instigates platelet aggregation, this will result in a lower platelet count during harvest, especially in traditional PRP following a hard spin!
i-PRF is an all natural autologous treatment that stimulates hair growth where hair follicles are present but inactive.
Research shows that the higher concentration of platelets, leukocytes and presence of fibrin is superior to PRP as it can enhance the growth of hair follicles by stimulating the stem cells and other cells in the microenvironment of the hair follicle.
Fibrin functions as a matrix that traps the platelets and controls their release of growth factors “very slowly and continuously over 7-10 days. Growth factors release rate into the target tissue is important for tissue receptors to respond over a prolonged period of time following treatment.
Platelets release 7 fundamental growth factors: PDGF, FGF, VEGF, EGF, KGF, IGF, TGF-β
For patients with significant hair loss, then a combined approach is often recommended, i-PRF works well for both men and women, especially those in the early stages of hair loss.
Injectable platelet‐rich fibrin stimulates greater dermal skin fibroblast cell migration, proliferation, and collagen synthesis when compared to platelet‐rich plasma.
Skin fibroblasts migrated over 350% more with i-PRF when compared to PRP (200% increase). i-PRF also significantly induces greater cell proliferation and significantly greater ability to induce collagen matrix synthesis when compared to PRP.
i-PRF yields more than double the number of platelets which play a critical role in tissue repair and regeneration, they regulate fundamental mechanisms involved in the healing process including cellular migration, proliferation, and angiogenesis.
i-PRF is proven to be the gold standard in natural skin rejuvenation. One of the main advantages of using i-PRF as a regenerative modality in various fields of regenerative medicine is its low cost in comparison with other regenerative modalities or recombinant growth factors/hormones.
This therapy is entirely autologous without any chemical additive and offers superior tissue bio-compatibility and tissue regeneration due to the activated platelets and fibrin matrix.
Furthermore, wound healing is drastically improved with i-PRF when compared to PRP as PRP typically contains low concentrations of leukocytes. Leukocytes are the main protagonists in wound healing and the regeneration process. Their presence in autologous therapy increases the regeneration capacity.
IN THE PRESS
iPRF Smart Cell Centrifuge is the smallest centrifuge on the market capable of hosting up to 6 x 13ml tubes.
It has been pre-configured with our customized i-PRF Smart Cell settings, and retains the ability to be set manually should the user feel the need to use a different centrifugation speed and time.
DOWNLOAD i-PRF Smart Cell Centrifuge Brochure
We offer 2 different kits.
Kit Option 1: contains 2 x 12ml tubes and will yield 4-8 ml of conditioned plasma. Kit price £45.00
Kit Option 2: contains 4 x 12ml tubes and will yield 8-16 ml of conditioned plasma. Kit price £70.00
Note: conditioned plasma is client dependent.
Treatment Kit Contents:
2 x Blood collection 21G butterfly
2 x Luer-lock 2.5ml syringe
2 x Meso-relle needle 30G x 4mm
2 x 30G 1 ½” sharp needle
2 x 30G x 13mm needle
12ml i-PRF Smart Cell vacutainers (2 or 4)
i-PRF Smart Cell vacutainers (12ml) for Injectable Platelet Rich Fibrin (iPRF) in aesthetics.
Unlike other tubes, the Smart Cell vacutainers come in individual sterile blister packs.
Class IIb medical device.
The tubes comply with all regulatory requirements by the EU Directive 93/42/EEC (CE 0123).
Login/register to the online shop for prices.
Medical Device EU Directive
i-PRF Smart Cell tubes are CE 0123, Class IIb Medical Device according to European Commission’s MEDDEV 93/42/EEC, Classification Document Annex IX with the Rule 3 that requires clinical evaluation and biocompatibility tests that lead to the permission of clinical applications.
Anita Woolley, FIBMS. | Senior Biomedical Scientist |
Article in Journal of Cosmetic Dermatology · April 2019
Shaoheng Xiong, M.D., Lihong Qiu, M.D., Yinjun Su, M.D., Ph.D., Hui Zheng, M.D., Chenggang Yi, M.D., Ph.D.
Balaram Naik, P Karunakar, M Jayadev, and V Rahul Marshal
Soh Nishimoto,corresponding author Kazutoshi Fujita, Yohei Sotsuka, Masato Kinoshita, Toshihiro Fujiwara, Kenichiro Kawai, and Masao Kakibuchi
Kian Karimi, M.D., Helena Rockwell, B.Sc.
Sercan Gode, M.D., Arin Ozturk, M.D., Erkan Kısmalı, M.D., Veysel Berber, M.D., Goksel Turhal, M.D. | Facial Plast Surg | 2019
Sercan Gode, M.D., Arin Ozturk, M.D., Veysel Berber, M.D., Erkan Kısmalı, M.D. | Facial Plast Surg | 2019